ArticleBreast cancer (Tokyo, Japan)2023
Characteristics of female breast cancer in japan: annual report of the National Clinical Database in 2018.
Article in Breast cancer (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial.Breast cancer (Tokyo, Japan) · 2025Trial
- The Ratio of the Resected Specimen Volume to Breast Volume, as Measured by Three-Dimensional Surface Imaging, Is Associated With Aesthetic Outcome After Breast-Conserving Surgery.European journal of breast health · 2026Article
- Annual report of national clinical database-breast cancer registry in 2023: systemic therapy for small breast cancer.Breast cancer (Tokyo, Japan) · 2026Article
- Prognostic impact of progesterone receptor status in patients with breast cancer and isolated locoregional recurrence.Breast cancer (Tokyo, Japan) · 2026Article
- Global longitudinal strain decline after anthracyclines in a relatively low-risk Japanese breast cancer cohort.Heart and vessels · 2026Article
- Real-world analysis of interstitial lung disease/pneumonitis in Japanese patients with breast cancer receiving trastuzumab deruxtecan.Breast cancer (Tokyo, Japan) · 2026Observational
- Cost-effectiveness analysis of the Oncotype DX Breast Recurrence ScoreBreast cancer (Tokyo, Japan) · 2026Article
- Phyto-Assisted Synthesis of Silver Nanoparticles (Ag-NPs) Using Delonix elata Extract: Characterization, Antimicrobial, Antioxidant, Anti-Inflammatory, and Photocatalytic Activities.Molecular biotechnology · 2026Article
- Article
- A cell-based model approach to radiation-induced breast cancer development.Frontiers in public health · 2026Article
- Quality of Life and Metabolomics Analysis in Response to Meal Kit Intervention During Perioperative Chemotherapy in Patients with Early-Stage Breast Cancer: Protocol for a Single-Center Phase Ⅱ Randomized Crossover Trial.JMIR research protocols · 2025Article
- Advancing breast cancer research through real-world data from the Singapore Joint Breast Cancer Registry.ESMO real world data and digital oncology · 2025Article
- Impact of the COVID-19 pandemic on breast cancer diagnosis and treatment trends in Japan.Breast cancer (Tokyo, Japan) · 2025Article
- Annual report of National Clinical Database-Breast Cancer Registry in 2021: characteristics categorized by body mass index and menopause status.Breast cancer (Tokyo, Japan) · 2025Article
- Article
- Breast cancer statistics for Japan in 2022: annual report of the national clinical database-breast cancer registry-clinical implications including chemosensitivity of breast cancer with low estrogen receptor expression.Breast cancer (Tokyo, Japan) · 2025Article
- CDK4/6 inhibitor plus endocrine therapy for advanced breast cancer: results from a web-based survey in Japan.Future oncology (London, England) · 2025Article
- Economic impact of screening on postdiagnosis work productivity in Japanese women with breast cancer: a life-table modeling approach.Breast cancer (Tokyo, Japan) · 2025Article
- Safety and pharmacokinetics of vepdegestrant in Japanese patients with ER+ advanced breast cancer: a phase 1 study.International journal of clinical oncology · 2025Article
- Comparison of locoregional recurrence risk among nipple-sparing mastectomy, skin-sparing mastectomy, and simple mastectomy in patients with ductal carcinoma in situ: a single-center study.Breast cancer (Tokyo, Japan) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Information regarding patients who were treated for breast cancer in 2018 was extracted from the National Clinical Database (NCD), which is run by Japanese physicians. This database continues from 1975, created by the Japanese Breast Cancer Society (JBCS). A total of 95,620 breast cancer cases were registered. The demographics, clinical characteristics, pathology, surgical treatment, adjuvant chemotherapy, adjuvant endocrine therapy, and radiation therapy of Japanese breast cancer patients were summarized. We made comparisons with other reports to reveal the characteristics of our database. We also described some features in Japanese breast cancer that changed over time. The unique characteristics of breast cancer patients in Japan may provide guidance for future research and improvement in healthcare services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.